Recent advances in the treatment of triple-negative breast cancer

被引：1

作者：

Pogoda, Katarzyna ^{[1
]}

Jagiello-Gruszfeld, Agnieszka ^{[1
]}

Kunkiel, Michal ^{[1
]}

Niwinska, Anna ^{[1
]}

Nowecki, Zbigniew ^{[1
]}

机构：

[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Breast Canc & Reconstruct Surg, Ul Roentgena 5, PL-02781 Warsaw, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2023年 / 19卷 / 06期

关键词：

triple-negative breast cancer; immunotherapy; olaparib; talazoparib; atezolizumab; pembrolizumab; sacituzumab govitecan; PEMBROLIZUMAB PLUS CHEMOTHERAPY; PATIENT-REPORTED OUTCOMES; GERMLINE BRCA MUTATION; CLINICAL-PRACTICE; SURVIVAL; OLAPARIB; PLACEBO; TRIAL; ATEZOLIZUMAB; PACLITAXEL;

D O I：

10.5603/OCP.2022.0056

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative is the rarest breast cancer biological subtype of breast cancer, but has the most aggressive course. The resuls of chemotherapy, especially in advanced disease, are unsatisfactory. Numerous clinical trials have been conducted, that resulted in registrations of new drugs decreasing the risk of recurrence and improving the outcome of patients with metastatic disease. The article summarizes the data on modern therapies registered in recent years. The role of pembrolizumab in perioperative treatment in the early stage was indicated, as well as the importance of olaparib in BRCA mutation carriers. Additionally, in patients with metastatic the indication for immunotherapy (pembrolizumab and atezolizumab), sacituzumab govitecan and PARP inhibitors (olaparib and talazoparib) in BRCA mutation carriers were highlighted.

引用

页码：433 / 443

页数：11

共 35 条

[1] Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer [J].

Adams, S. ;

Dieras, V. ;

Barrios, C. H. ;

Winer, E. P. ;

Schneeweiss, A. ;

Iwata, H. ;

Loi, S. ;

Patel, S. ;

Henschel, V. ;

Chui, S. Y. ;

Rugo, H. S. ;

Emens, L. A. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2020, 31 (05) :582-589

[2]

[Anonymous], 2022, Charakterystyka Produktu Leczniczego Keytruda

[3]

[Anonymous], 2022, rogram lekowy. Leczenie chorych na raka piersi

[4]

B9FM od 11.2022

[5]

[Anonymous], 2022, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer

[6] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[7]

Bardia A, 2022, J CLIN ONCOL, V40

[8] Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials [J].

Boddington, C. ;

Bradley, R. ;

Braybrooke, J. ;

Burrett, J. ;

Clarke, M. ;

Davies, C. ;

Davies, L. ;

Dodwell, D. ;

Duane, F. ;

Evans, V. ;

Gettins, L. ;

Godwin, J. ;

Gray, R. ;

Hills, R. ;

James, S. ;

Liu, H. ;

Liu, Z. ;

MacKinnon, E. ;

Mannu, G. ;

McGale, P. ;

McHugh, T. ;

Morris, P. ;

Pan, H. ;

Peto, R. ;

Read, S. ;

Taylor, C. ;

Wang, Y. ;

Wang, Z. ;

Bradley, R. ;

Braybrooke, J. ;

Gray, R. ;

Bergh, J. ;

Peto, R. ;

Gray, Richard ;

Bradley, Rosie ;

Braybrooke, Jeremy ;

Liu, Zulian ;

Peto, Richard ;

Davies, Lucy ;

Dodwell, David ;

McGale, Paul ;

Pan, Hongchao ;

Taylor, Carolyn ;

Barlow, William ;

Bliss, Judith ;

Bruzzi, Paolo ;

Cameron, David ;

Fountzilas, George ;

Loibl, Sibylle ;

Mackey, John .

LANCET, 2019, 393 (10179) :1440-1452

[9] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J].

Burstein, H. J. ;

Curigliano, G. ;

Thurlimann, B. ;

Weber, W. P. ;

Poortmans, P. ;

Regan, M. M. ;

Senn, H. J. ;

Winer, E. P. ;

Gnant, M. .

ANNALS OF ONCOLOGY, 2021, 32 (10) :1216-1235

Cescon, D. W. ;

Schmid, P. ;

Rugo, H. S. ;

Im, S-A. ;

Yusof, M. Md ;

Gallardo, C. E. ;

Lipatov, O. ;

Barrios, C. H. ;

Perez Garcia, J. M. ;

Iwata, H. ;

Masuda, N. ;

Torregroza Otero, M. A. ;

Gokmen, E. ;

Loi, S. ;

Haiderali, A. ;

Zhou, X. ;

Guo, Z. ;

Nguyen, A. Martin ;

Cortes, J. .

ANNALS OF ONCOLOGY, 2022, 33 :S197-S198

← 1 2 3 4 →